Evolent Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EVH research report →
Range $7 – $7
Price Chart
About the company
Evolent Health, Inc. , a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions.
- CEO
- Seth Barrie Blackley
- IPO
- 2015
- Employees
- 4,200
- HQ
- Arlington, VA, US
Get TickerSpark's AI analysis on EVH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $438.68M
- P/E
- -0.77
- Fwd P/E
- 17.28
- PEG
- 0.00
- P/S
- 0.16
- P/B
- 1.04
- EV/EBITDA
- -3.73
- Div Yield
- 0.00%
- Gross Margin
- 12.10%
- Op Margin
- -0.99%
- Net Margin
- -21.67%
- ROE
- -129.54%
- ROIC
- -1.57%
Latest fiscal year · YoY change
- Revenue
- $1.88B-26.6%
- Gross Profit
- $284.03M-22.7%
- Op Income
- $-4,435,000
- Net Income
- $-534,510,000-767.4%
- EPS
- $-5.07-525.9%
- OCF Growth
- +107.0%
- FCF Growth
- +177.6%
- 52W High
- $6.26
- 52W Low
- $2.10
- 50D MA
- $4.22
- 200D MA
- $3.94
- Beta
- 0.84
- RSI (14)
- 32
- Avg Volume
- 2.12M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Evolent delivered another sequentially stronger quarter, lifted full-year Adjusted EBITDA guidance, and highlighted customer renewals/expansions plus AI-driven efficiency as key growth and margin drivers.· November 5, 2026
- Q3 revenue was $725 million, up 11% sequentially, and Adjusted EBITDA was $34 million to $34.3 million, up about 22% sequentially.
- MER improved to 93% from 95% in Q2, helped by favorable in-year claims development and contractual adjustments.
- Full-year revenue guidance was reaffirmed at $2.6 billion-$2.7 billion, while full-year Adjusted EBITDA guidance was raised to $130 million-$135 million.
- Management highlighted major customer wins: a four-year renewal of the largest Surgical Management contract, an oncology expansion adding about 1 million commercial lives, and a specialty technology expansion adding 11 states.
- AuthIntelligence is now handling about half of prior-auth volume that used to require manual review, touching about 1 million cases per year, with more than 80% of manual auths expected to run through it by end-2027.
Evolent reported third-quarter revenue of $725 million, up approximately 11% versus Q2, and Adjusted EBITDA of $34 million to $34.3 million, up approximately 22% sequentially. Performance Suite revenue was $564 million, up approximately 16% quarter-over-quarter; Specialty Technology and Services revenue was $73 million, down approximately 7%; Administrative Services revenue was $48 million, roughly flat; and Cases revenue was about $40 million. Medical expense ratio was 93% versus 95% in Q2, an approximately 220 basis-point improvement. The company ended the quarter with unrestricted cash of $148 million and net debt of $776 million, and Q3 operating cash flow was approximately $26 million with capital expenditures of about $7 million. For the full year, Evolent reiterated revenue guidance of $2.6 billion-$2.7 billion, raised Adjusted EBITDA guidance to $130 million-$135 million from $120 million-$135 million, maintained a full-year MER of approximately 93%, kept adjusted cost of revenue plus adjusted SG&A at approximately $675 million, expects cash flow from operations of $10 million-$20 million after about $60 million of annual cash interest expense, and now expects capital expenditures of $26 million-$28 million. For Q4, management expects a sequential increase in Adjusted EBITDA of approximately $11 million-$16 million. Looking ahead to 2027, management said it still expects strong revenue growth led by Performance Suite and said the midpoint of 2027 Adjusted EBITDA guidance will be $150 million or higher, while detailed 2027 revenue guidance will be provided with fourth-quarter results in February.
Seth Blackley framed the quarter as evidence that Evolent is executing on growth, profitability, and customer retention at the same time. He emphasized renewals and expansions as proof that customers want more of Evolent’s platform, and he repeatedly pointed to oncology and AI as the biggest strategic pillars. His tone was confident and upbeat, especially on the company’s competitive position in oncology and the long-term margin and market-share potential from AuthIntelligence.
Mario Ramos focused on the quarter’s financial progression and the mechanics behind the margin improvement. He said the 93% MER reflected earlier-than-expected favorable in-year claims development, and he noted Q4 should still improve sequentially, though less than previously expected because some benefit already flowed through in Q3. He also highlighted cash generation, ending cash of $148 million, net debt of $776 million, and reiterated the company’s capital allocation plan to deploy up to $50 million toward reducing indebtedness by year-end while keeping flexibility around timing and form.
Analysts pressed on 2027 medical cost assumptions, and management said they are broadly assuming trend stability over the next 12 months, with contract profitability improving as contracts mature. Questions on strategic alternatives and refinancing drew a response that Evolent is evaluating everything that could make sense for shareholders, but the near-term priority is deleveraging and refinancing. There were also questions about the oncology expansion and the Aetna relationship; management said the 1 million-live expansion is a T&S-type opportunity and that the Aetna work discussed in the news is Medicaid, not the company’s Medicare work, so there is no change to the Florida relationship.
The bull case from this call is that Evolent is seeing renewals, expansions, and product breadth increases all at once, suggesting customers are leaning in rather than pulling back. Management also sounded increasingly constructive on AuthIntelligence, saying it can reduce manual touches meaningfully, support margin expansion, and help win more share over time.
The main risks flagged on the call are membership attrition, scope adjustments from renewals, and continued upfront investment in AI and other growth initiatives that could weigh on near-term economics. Management also acknowledged that some 2027 benefits are not yet locked in, with revenue growth depending on timing of new launches, Medicaid/exchange membership trends, and contract scope outcomes, while some AI benefits may not show up until late 2027 and beyond.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 91.1%
- Shares Outstanding
- 112.48M
- Float Shares
- 102.45M
of shares held by institutions
207 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for EVH, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 15.78M | ▲ 965.12K |
| Cadian Capital Management, LP | 10.81M | 0 |
| Vanguard Group Inc | 8.91M | ▼ 2.05M |
| Rubicon Founders LLC | 5.64M | ▼ 175.00K |
| Engaged Capital LLC | 5.56M | 0 |
| Marshall Wace, Llp | 5.32M | ▲ 1.91M |
| D. E. Shaw & Co., Inc. | 5.11M | ▼ 326.47K |
| Vanguard Capital Management LLC | 4.68M | ▼ 104.23K |
| Nuveen, LLC | 3.91M | ▲ 773.92K |
| Vanguard Portfolio Management LLC | 3.34M | ▲ 2.00M |
| State Street Corp | 2.51M | ▲ 53.64K |
| Rock Springs Capital Management LP | 2.50M | ▼ 175.00K |
Held by 182 ETFs
Biggest fund positions in EVH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 26, 26 | McCarthy Daniel Joseph | sell | 65,892 |
| Jul 1, 26 | Blackley Seth | other | 446,102 |
| Jul 1, 26 | Blackley Seth | other | 10,297 |
| Jul 1, 26 | Weinberg Jonathan | other | 43,055 |
| Jul 1, 26 | Weinberg Jonathan | other | 2,650 |
| Jul 1, 26 | McCarthy Daniel Joseph | other | 302,585 |
| Jul 1, 26 | McCarthy Daniel Joseph | other | 4,582 |
| Jul 1, 26 | Shams Aammaad | other | 28,790 |
| Jun 4, 26 | Ajayi Toyin | other | 41,096 |
| Jun 4, 26 | Glass Russell Monroe | other | 41,096 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EVH coverage
Recent articles, reports, and earnings notes.
Want a deeper read on EVH?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Financial Review: Evolent Health (EVH) and Its Competitors
defenseworld.net · Nov 11
Evolent Health, Inc. (EVH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
What Evolent Health (EVH) Said on Its Q3 Earnings Call
marketbeat.com · Nov 7
Evolent Health (EVH) Matches Q3 Earnings Estimates
zacks.com · Nov 5
Compared to Estimates, Evolent Health (EVH) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 5
Evolent Announces Third Quarter 2026 Results
prnewswire.com · Nov 5
Analyzing CareCloud (NASDAQ:CCLD) & Evolent Health (NYSE:EVH)
defenseworld.net · Oct 16
Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026
prnewswire.com · Oct 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
